Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-inflammatory therapy for COVID-19 infection: the case for colchicine
Aaron Reyes, Kelly A Hu, Jacob Teperman, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 5, pp. 550-557
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Inflammasome activation at the crux of severe COVID-19
Setu M. Vora, Judy Lieberman, Hao Wu
Nature reviews. Immunology (2021) Vol. 21, Iss. 11, pp. 694-703
Open Access | Times Cited: 288
Prospective Roles of Tumor Necrosis Factor-Alpha (TNF-α) in COVID-19: Prognosis, Therapeutic and Management
Zarina Mohd Zawawi, Jeevanathan Kalyanasundram, Rozainanee Mohd Zain, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6142-6142
Open Access | Times Cited: 41
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions
Robert Root‐Bernstein
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 2108-2108
Open Access | Times Cited: 95
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Timotius Ivan Hariyanto, Devina Adella Halim, Claudia Jodhinata, et al.
Clinical and Experimental Pharmacology and Physiology (2021) Vol. 48, Iss. 6, pp. 823-830
Open Access | Times Cited: 74
Brief review of the mRNA vaccines COVID-19
Antonio Vitiello, Francesco Ferrara
Inflammopharmacology (2021) Vol. 29, Iss. 3, pp. 645-649
Open Access | Times Cited: 61
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
Antonio Vitiello, Francesco Ferrara
Respiratory Medicine (2021) Vol. 178, pp. 106322-106322
Open Access | Times Cited: 58
Colchicine for the treatment of COVID-19
Agata Mikołajewska, Anna-Lena Fischer, Vanessa Piechotta, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 58
Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
Aldo Bonaventura, Alessandra Vecchiè, Lorenzo Dagna, et al.
Inflammation Research (2022) Vol. 71, Iss. 3, pp. 293-307
Open Access | Times Cited: 42
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
Sawsan Aboul‐Fotouh, Ahmed N. Mahmoud, Esraa M. Elnahas, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 29
Fatal attractions that trigger inflammation and drive atherosclerotic disease
Hitesh Sharma, Karen L. Mossman, Richard C. Austin
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 5
Open Access | Times Cited: 8
Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity
Ruoyue Huang, Jingyi Duan, Wen Huang, et al.
Toxins (2024) Vol. 16, Iss. 1, pp. 35-35
Open Access | Times Cited: 7
NETosis and the Immune System in COVID-19: Mechanisms and Potential Treatments
Constant Gillot, Julien Favresse, François Mullier, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 48
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Jienchi Dorward, Ly‐Mee Yu, Gail Hayward, et al.
British Journal of General Practice (2022) Vol. 72, Iss. 720, pp. e446-e455
Open Access | Times Cited: 32
Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial
Adel A. Gomaa, Hamdy Saad Mohamed, Rasha B. Abd-ellatief, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 2, pp. 477-486
Open Access | Times Cited: 29
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Jiaying Shen, Junyan Fan, Yue Zhao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 17
Exploring neutrophils as therapeutic targets in cardiometabolic diseases
Mattia Albiero, Andrea Baragetti
Trends in Pharmacological Sciences (2025)
Closed Access
Alkaloids Derived from Tyrosine: Phenethylisoquinoline (Colchicine)
Mihir Halder, Pijush Paul, Sumita Jha
Springer eBooks (2025), pp. 1-36
Closed Access
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19
Rafael Díaz, Andrés Orlandini, Noelia Castellana, et al.
JAMA Network Open (2021) Vol. 4, Iss. 12, pp. e2141328-e2141328
Open Access | Times Cited: 35
Coronavirus disease 2019 (COVID-19) and autoimmunity
Е. Л. Насонов
Rheumatology Science and Practice (2021) Vol. 59, Iss. 1, pp. 5-30
Open Access | Times Cited: 32
Synthesis of Seleno-Dibenzocycloheptenones/Spiro[5.5]Trienones by Radical Cyclization of Biaryl Ynones
Helen A. Goulart, Ricardo H. Bartz, Thiago J. Peglow, et al.
The Journal of Organic Chemistry (2022) Vol. 87, Iss. 6, pp. 4273-4283
Closed Access | Times Cited: 26
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Fatma Haddad, Ghadeer Dokmak, Rafik Karaman
Life (2022) Vol. 12, Iss. 11, pp. 1758-1758
Open Access | Times Cited: 22
Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials
Huzaifa Ahmad Cheema, Uzair Jafar, Abia Shahid, et al.
BMJ Open (2024) Vol. 14, Iss. 4, pp. e074373-e074373
Open Access | Times Cited: 4
Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids
M. Torres, Sebastià Parets, Javier Fernández-Díaz, et al.
Membranes (2021) Vol. 11, Iss. 12, pp. 919-919
Open Access | Times Cited: 30
Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients
Lealem Gedefaw, Sami Ullah, Polly H. M. Leung, et al.
Cells (2021) Vol. 10, Iss. 4, pp. 916-916
Open Access | Times Cited: 29
Combination therapies for COVID‐19: An overview of the clinical trials landscape
Sola Akinbolade, Diarmuid Coughlan, Ross Fairbairn, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1590-1597
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top